文章摘要
冯健男,乔春霞.人源治疗性抗体研发技术进展[J].南京医科大学学报,2020,(11):1571~1574
人源治疗性抗体研发技术进展
Progression on research technology of human therapeutic antibody
投稿时间:2020-10-27  
DOI:10.7655/NYDXBNS20201101
中文关键词: 治疗性抗体  抗体人源化  噬菌体展示  转基因小鼠  单细胞PCR
英文关键词: therapeutic antibody  antibody humanization  phage display  transgenic mice  single cell PCR
基金项目:国家自然科学基金(31771010)
作者单位
冯健男 军事科学院军事医学研究院毒物药物研究所重大疫情应急防控药物研究室北京 100850 
乔春霞 军事科学院军事医学研究院毒物药物研究所重大疫情应急防控药物研究室北京 100850 
摘要点击次数: 1151
全文下载次数: 1027
中文摘要:
      1986年美国食品和药物管理局(Food and Drug Administration,FDA)批准了首个单抗药物。30多年来,抗体药物领域的发展日新月异,截至2019年12月,获得FDA批准上市的单抗药物达79种,用于治疗癌症、自身免疫性疾病、传染病等多种疾病。人源抗体具有特异性强、不良反应小的优点,已经成为新药开发的主流,全球销售额排名前十的药物中,人源抗体药物占据了半壁江山。本文着重对近年来抗体药物研发技术进展,包括抗体人源化、噬菌体展示、转基因小鼠、单细胞PCR等进行述评。
英文摘要:
      The first monoclonal antibody was approved by the Food and Drug Administration(FDA) in 1986. Over the past 30 years,the antibody field has developed rapidly. By December 2019,79 monoclonal antibodies have been approved by FDA for the treatment of cancer,autoimmune,infectious and other diseases. Antibodies have the advantages of high specificity and less side effects,and have become the mainstream of new drug development. Among the top ten biological drugs in the world,antibodies account for half of the total. This paper introduces the novel research technologies,including antibody humanization,phage display,transgenic mice,and single cell PCR,etc.
查看全文   查看/发表评论  下载PDF阅读器